Phase 2a, randomized, double-blind, placebo-controlled pilot study to investigate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of two doses of JNJ-53718678 in non-hospitalized adult patients infected with respiratory syncytial virus
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Sponsor: JANSSEN SCIENCES IRELAND UC
- Phase: II
- Execution start: 10/01/2018
- End of execution: 30/08/2020
- PI: JUAN PASQUAU LIAÑO